 Global Targeted Protein Degraders Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Targeted Protein Degraders market size was US$ 133 million in 2025 and is forecast to reach a readjusted size of US$ 422 million by 2032 with a CAGR of 18.3% during the forecast period 2... もっと見る
SummaryThe global Targeted Protein Degraders market size was US$ 133 million in 2025 and is forecast to reach a readjusted size of US$ 422 million by 2032 with a CAGR of 18.3% during the forecast period 2026-2032.Targeted protein degraders are a promising class of drugs that have gained significant attention in recent years due to their potential to treat previously "undruggable" targets in diseases such as cancer. Protein degradation is the process by which proteins are naturally destroyed in a cell in order to maintain protein homeostasis, or an equilibrium of proteins in the human body. The body is constantly making and remaking proteins (creation), while also removing ones that have become inactive or mutated (degradation). When a cell is unable to degrade certain proteins, the proteins can accumulate, causing diseases like cancer. With targeted protein degradation, researchers are harnessing the cell’s own machinery to degrade several whole new classes of proteins that were previously considered “undruggable.” Scientists are leveraging three different modalities of targeted protein degradation – molecular glues, also called CELMoDTM agents, ligand-directed degraders (LDDs) and antibody drug conjugate (ADC) degraders. This three-pronged approach provides more opportunities for breakthroughs and therapeutic strategies that could one day offer meaningful new options for patients across a broad range of diseases including certain types of myeloma, lymphoma, solid tumors and myelodysplastic syndromes, as well as sickle cell disease. The market for targeted protein degraders is experiencing rapid growth, driven by increasing interest in novel therapeutic modalities that go beyond traditional small molecules and biologics. Technologies such as PROTACs (proteolysis-targeting chimeras) and molecular glues are gaining traction due to their ability to eliminate disease-causing proteins rather than merely inhibiting them. This approach is particularly promising for previously “undruggable” targets in oncology, neurodegenerative diseases, and autoimmune conditions. The field is seeing strong investment from both biotech startups and large pharmaceutical companies, along with a growing pipeline of candidates advancing through preclinical and clinical stages. Strategic collaborations, academic partnerships, and advancements in E3 ligase biology and structure-based drug design are further propelling innovation in this emerging sector. The global Targeted Protein Degraders market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032. Market Segmentation By Company: Arvinas C4 Therapeutics Kymera Therapeutics Nurix Pfizer Novartis MSD Foghorn Therapeutics Dialectic Therapeutics Accutar Biotech Cullgen Bristol-Myers Squibb Monte Rosa Therapeutics Proxygen Dunad Therapeutics Astellas Origami Therapeutics NEOsphere Biotechnologies Ubiquigent Kangpu Biopharmaceuticals Ranok Therapeutics BeiGene Hinova Pharma Haisco Pharmaceutical CTTQ Segment by Type PROTAC Molecular Glues Other Ubiquitin-Proteasome System Technologies Lysosomal System Technologies Segment by Application Prostate Cancer Breast Cancer Lymphoma Others Macro-Region - North America - Europe - Asia-Pacific - South America - Middle East & Africa Micro-Local Market North America Europe China Japan Chapter Outline Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term Chapter 2: Quantitative analysis of Targeted Protein Degraders sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region Chapter 3: Competitive landscape of Targeted Protein Degraders manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans) Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment) Chapter 7: Key manufacturer profiles –company overview, Targeted Protein Degraders product descriptions and specifications, revenue, gross margins, and recent developments Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies Chapter 11: Key findings, main takeaways, and overall conclusions of the report. Why This Report? Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Targeted Protein Degraders value chain, addressing: - Market entry risks/opportunities by region - Product mix optimization based on local practices - Competitor tactics in fragmented vs. consolidated markets Table of Contents1 Market Overview1.1 Targeted Protein Degraders Product Scope 1.2 Targeted Protein Degraders by Type 1.2.1 Global Targeted Protein Degraders Sales by Type (2021, 2025 & 2032) 1.2.2 PROTAC 1.2.3 Molecular Glues 1.2.4 Other Ubiquitin-Proteasome System Technologies 1.2.5 Lysosomal System Technologies 1.3 Targeted Protein Degraders by Application 1.3.1 Global Targeted Protein Degraders Sales Comparison by Application (2021, 2025 & 2032) 1.3.2 Prostate Cancer 1.3.3 Breast Cancer 1.3.4 Lymphoma 1.3.5 Others 1.4 Global Targeted Protein Degraders Market Estimates and Forecasts (2021-2032) 1.4.1 Global Targeted Protein Degraders Market Size (Value) and Growth Rate (2021-2032) 1.4.2 Global Targeted Protein Degraders Market Size (Volume) and Growth Rate (2021-2032) 1.4.3 Global Targeted Protein Degraders Price Trends (2021-2032) 1.5 Assumptions and Limitations 2 Market Size and Prospects by Region 2.1 Global Targeted Protein Degraders Market Size by Region: 2021 VS 2025 VS 2032 2.2 Global Targeted Protein Degraders Historical Market Scenario by Region (2021-2026) 2.2.1 Global Targeted Protein Degraders Sales Market Share by Region (2021-2026) 2.2.2 Global Targeted Protein Degraders Revenue Market Share by Region (2021-2026) 2.3 Global Targeted Protein Degraders Market Estimates and Forecasts by Region (2027-2032) 2.3.1 Global Targeted Protein Degraders Sales Estimates and Forecasts by Region (2027-2032) 2.3.2 Global Targeted Protein Degraders Revenue Forecast by Region (2027-2032) 2.4 Major Regions and Emerging Market Analysis 2.4.1 North America Targeted Protein Degraders Market Size and Prospects (2021-2032) 2.4.2 Europe Targeted Protein Degraders Market Size and Prospects (2021-2032) 2.4.3 China Targeted Protein Degraders Market Size and Prospects (2021-2032) 2.4.4 Japan Targeted Protein Degraders Market Size and Prospects (2021-2032) 3 Global Market Size by Type 3.1 Global Targeted Protein Degraders Historical Market Review by Type (2021-2026) 3.1.1 Global Targeted Protein Degraders Sales by Type (2021-2026) 3.1.2 Global Targeted Protein Degraders Revenue by Type (2021-2026) 3.1.3 Global Targeted Protein Degraders Average Price by Type (2021-2026) 3.2 Global Targeted Protein Degraders Market Estimates and Forecasts by Type (2027-2032) 3.2.1 Global Targeted Protein Degraders Sales Forecast by Type (2027-2032) 3.2.2 Global Targeted Protein Degraders Revenue Forecast by Type (2027-2032) 3.2.3 Global Targeted Protein Degraders Price Forecast by Type (2027-2032) 3.3 Representative Players for Different Types of Targeted Protein Degraders 4 Global Market Size by Application 4.1 Global Targeted Protein Degraders Historical Market Review by Application (2021-2026) 4.1.1 Global Targeted Protein Degraders Sales by Application (2021-2026) 4.1.2 Global Targeted Protein Degraders Revenue by Application (2021-2026) 4.1.3 Global Targeted Protein Degraders Average Price by Application (2021-2026) 4.2 Global Targeted Protein Degraders Market Estimates and Forecasts by Application (2027-2032) 4.2.1 Global Targeted Protein Degraders Sales Forecast by Application (2027-2032) 4.2.2 Global Targeted Protein Degraders Revenue Forecast by Application (2027-2032) 4.2.3 Global Targeted Protein Degraders Price Forecast by Application (2027-2032) 4.3 New Sources of Growth in Targeted Protein Degraders Applications 5 Competition Landscape by Players 5.1 Global Targeted Protein Degraders Sales by Player (2021-2026) 5.2 Global Top Targeted Protein Degraders Players by Revenue (2021-2026) 5.3 Global Targeted Protein Degraders Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on Targeted Protein Degraders revenue as of 2025 5.4 Global Targeted Protein Degraders Average Price by Company (2021-2026) 5.5 Global Key Manufacturers of Targeted Protein Degraders, Manufacturing Sites & Headquarters 5.6 Global Key Manufacturers of Targeted Protein Degraders, Product Type & Application 5.7 Global Key Manufacturers of Targeted Protein Degraders, Date of Entry into This Industry 5.8 Manufacturers Mergers & Acquisitions, Expansion Plans 6 Regional Analysis 6.1 North America Market: Players, Segments, Downstream and Major Customers 6.1.1 North America Targeted Protein Degraders Sales by Company 6.1.1.1 North America Targeted Protein Degraders Sales by Company (2021-2026) 6.1.1.2 North America Targeted Protein Degraders Revenue by Company (2021-2026) 6.1.2 North America Targeted Protein Degraders Sales Breakdown by Type (2021-2026) 6.1.3 North America Targeted Protein Degraders Sales Breakdown by Application (2021-2026) 6.1.4 North America Targeted Protein Degraders Major Customers 6.1.5 North America Market Trends and Opportunities 6.2 Europe Market: Players, Segments, Downstream and Major Customers 6.2.1 Europe Targeted Protein Degraders Sales by Company 6.2.1.1 Europe Targeted Protein Degraders Sales by Company (2021-2026) 6.2.1.2 Europe Targeted Protein Degraders Revenue by Company (2021-2026) 6.2.2 Europe Targeted Protein Degraders Sales Breakdown by Type (2021-2026) 6.2.3 Europe Targeted Protein Degraders Sales Breakdown by Application (2021-2026) 6.2.4 Europe Targeted Protein Degraders Major Customers 6.2.5 Europe Market Trends and Opportunities 6.3 China Market: Players, Segments, Downstream and Major Customers 6.3.1 China Targeted Protein Degraders Sales by Company 6.3.1.1 China Targeted Protein Degraders Sales by Company (2021-2026) 6.3.1.2 China Targeted Protein Degraders Revenue by Company (2021-2026) 6.3.2 China Targeted Protein Degraders Sales Breakdown by Type (2021-2026) 6.3.3 China Targeted Protein Degraders Sales Breakdown by Application (2021-2026) 6.3.4 China Targeted Protein Degraders Major Customers 6.3.5 China Market Trends and Opportunities 6.4 Japan Market: Players, Segments, Downstream and Major Customers 6.4.1 Japan Targeted Protein Degraders Sales by Company 6.4.1.1 Japan Targeted Protein Degraders Sales by Company (2021-2026) 6.4.1.2 Japan Targeted Protein Degraders Revenue by Company (2021-2026) 6.4.2 Japan Targeted Protein Degraders Sales Breakdown by Type (2021-2026) 6.4.3 Japan Targeted Protein Degraders Sales Breakdown by Application (2021-2026) 6.4.4 Japan Targeted Protein Degraders Major Customers 6.4.5 Japan Market Trends and Opportunities 7 Company Profiles and Key Figures 7.1 Arvinas 7.1.1 Arvinas Company Information 7.1.2 Arvinas Business Overview 7.1.3 Arvinas Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.1.4 Arvinas Targeted Protein Degraders Products Offered 7.1.5 Arvinas Recent Development 7.2 C4 Therapeutics 7.2.1 C4 Therapeutics Company Information 7.2.2 C4 Therapeutics Business Overview 7.2.3 C4 Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.2.4 C4 Therapeutics Targeted Protein Degraders Products Offered 7.2.5 C4 Therapeutics Recent Development 7.3 Kymera Therapeutics 7.3.1 Kymera Therapeutics Company Information 7.3.2 Kymera Therapeutics Business Overview 7.3.3 Kymera Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.3.4 Kymera Therapeutics Targeted Protein Degraders Products Offered 7.3.5 Kymera Therapeutics Recent Development 7.4 Nurix 7.4.1 Nurix Company Information 7.4.2 Nurix Business Overview 7.4.3 Nurix Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.4.4 Nurix Targeted Protein Degraders Products Offered 7.4.5 Nurix Recent Development 7.5 Pfizer 7.5.1 Pfizer Company Information 7.5.2 Pfizer Business Overview 7.5.3 Pfizer Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.5.4 Pfizer Targeted Protein Degraders Products Offered 7.5.5 Pfizer Recent Development 7.6 Novartis 7.6.1 Novartis Company Information 7.6.2 Novartis Business Overview 7.6.3 Novartis Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.6.4 Novartis Targeted Protein Degraders Products Offered 7.6.5 Novartis Recent Development 7.7 MSD 7.7.1 MSD Company Information 7.7.2 MSD Business Overview 7.7.3 MSD Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.7.4 MSD Targeted Protein Degraders Products Offered 7.7.5 MSD Recent Development 7.8 Foghorn Therapeutics 7.8.1 Foghorn Therapeutics Company Information 7.8.2 Foghorn Therapeutics Business Overview 7.8.3 Foghorn Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.8.4 Foghorn Therapeutics Targeted Protein Degraders Products Offered 7.8.5 Foghorn Therapeutics Recent Development 7.9 Dialectic Therapeutics 7.9.1 Dialectic Therapeutics Company Information 7.9.2 Dialectic Therapeutics Business Overview 7.9.3 Dialectic Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.9.4 Dialectic Therapeutics Targeted Protein Degraders Products Offered 7.9.5 Dialectic Therapeutics Recent Development 7.10 Accutar Biotech 7.10.1 Accutar Biotech Company Information 7.10.2 Accutar Biotech Business Overview 7.10.3 Accutar Biotech Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.10.4 Accutar Biotech Targeted Protein Degraders Products Offered 7.10.5 Accutar Biotech Recent Development 7.11 Cullgen 7.11.1 Cullgen Company Information 7.11.2 Cullgen Business Overview 7.11.3 Cullgen Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.11.4 Cullgen Targeted Protein Degraders Products Offered 7.11.5 Cullgen Recent Development 7.12 Bristol-Myers Squibb 7.12.1 Bristol-Myers Squibb Company Information 7.12.2 Bristol-Myers Squibb Business Overview 7.12.3 Bristol-Myers Squibb Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.12.4 Bristol-Myers Squibb Targeted Protein Degraders Products Offered 7.12.5 Bristol-Myers Squibb Recent Development 7.13 Monte Rosa Therapeutics 7.13.1 Monte Rosa Therapeutics Company Information 7.13.2 Monte Rosa Therapeutics Business Overview 7.13.3 Monte Rosa Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.13.4 Monte Rosa Therapeutics Targeted Protein Degraders Products Offered 7.13.5 Monte Rosa Therapeutics Recent Development 7.14 Proxygen 7.14.1 Proxygen Company Information 7.14.2 Proxygen Business Overview 7.14.3 Proxygen Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.14.4 Proxygen Targeted Protein Degraders Products Offered 7.14.5 Proxygen Recent Development 7.15 Dunad Therapeutics 7.15.1 Dunad Therapeutics Company Information 7.15.2 Dunad Therapeutics Business Overview 7.15.3 Dunad Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.15.4 Dunad Therapeutics Targeted Protein Degraders Products Offered 7.15.5 Dunad Therapeutics Recent Development 7.16 Astellas 7.16.1 Astellas Company Information 7.16.2 Astellas Business Overview 7.16.3 Astellas Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.16.4 Astellas Targeted Protein Degraders Products Offered 7.16.5 Astellas Recent Development 7.17 Origami Therapeutics 7.17.1 Origami Therapeutics Company Information 7.17.2 Origami Therapeutics Business Overview 7.17.3 Origami Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.17.4 Origami Therapeutics Targeted Protein Degraders Products Offered 7.17.5 Origami Therapeutics Recent Development 7.18 NEOsphere Biotechnologies 7.18.1 NEOsphere Biotechnologies Company Information 7.18.2 NEOsphere Biotechnologies Business Overview 7.18.3 NEOsphere Biotechnologies Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.18.4 NEOsphere Biotechnologies Targeted Protein Degraders Products Offered 7.18.5 NEOsphere Biotechnologies Recent Development 7.19 Ubiquigent 7.19.1 Ubiquigent Company Information 7.19.2 Ubiquigent Business Overview 7.19.3 Ubiquigent Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.19.4 Ubiquigent Targeted Protein Degraders Products Offered 7.19.5 Ubiquigent Recent Development 7.20 Kangpu Biopharmaceuticals 7.20.1 Kangpu Biopharmaceuticals Company Information 7.20.2 Kangpu Biopharmaceuticals Business Overview 7.20.3 Kangpu Biopharmaceuticals Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.20.4 Kangpu Biopharmaceuticals Targeted Protein Degraders Products Offered 7.20.5 Kangpu Biopharmaceuticals Recent Development 7.21 Ranok Therapeutics 7.21.1 Ranok Therapeutics Company Information 7.21.2 Ranok Therapeutics Business Overview 7.21.3 Ranok Therapeutics Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.21.4 Ranok Therapeutics Targeted Protein Degraders Products Offered 7.21.5 Ranok Therapeutics Recent Development 7.22 BeiGene 7.22.1 BeiGene Company Information 7.22.2 BeiGene Business Overview 7.22.3 BeiGene Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.22.4 BeiGene Targeted Protein Degraders Products Offered 7.22.5 BeiGene Recent Development 7.23 Hinova Pharma 7.23.1 Hinova Pharma Company Information 7.23.2 Hinova Pharma Business Overview 7.23.3 Hinova Pharma Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.23.4 Hinova Pharma Targeted Protein Degraders Products Offered 7.23.5 Hinova Pharma Recent Development 7.24 Haisco Pharmaceutical 7.24.1 Haisco Pharmaceutical Company Information 7.24.2 Haisco Pharmaceutical Business Overview 7.24.3 Haisco Pharmaceutical Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.24.4 Haisco Pharmaceutical Targeted Protein Degraders Products Offered 7.24.5 Haisco Pharmaceutical Recent Development 7.25 CTTQ 7.25.1 CTTQ Company Information 7.25.2 CTTQ Business Overview 7.25.3 CTTQ Targeted Protein Degraders Sales, Revenue and Gross Margin (2021-2026) 7.25.4 CTTQ Targeted Protein Degraders Products Offered 7.25.5 CTTQ Recent Development 8 Targeted Protein Degraders Manufacturing Cost Analysis 8.1 Targeted Protein Degraders Key Raw Materials Analysis 8.1.1 Key Raw Materials 8.1.2 Key Suppliers of Raw Materials 8.2 Manufacturing Cost Structure 8.3 Manufacturing Process Analysis of Targeted Protein Degraders 8.4 Targeted Protein Degraders Industrial Chain Analysis 9 Marketing Channels, Distributors and Customers 9.1 Marketing Channels 9.2 Targeted Protein Degraders Distributors List 9.3 Targeted Protein Degraders Customers 10 Targeted Protein Degraders Market Dynamics 10.1 Targeted Protein Degraders Industry Trends 10.2 Targeted Protein Degraders Market Drivers 10.3 Targeted Protein Degraders Market Challenges 10.4 Targeted Protein Degraders Market Restraints 11 Research Findings and Conclusion 12 Appendix 12.1 Research Methodology 12.1.1 Methodology/Research Approach 12.1.1.1 Research Programs/Design 12.1.1.2 Market Size Estimation 12.1.1.3 Market Breakdown and Data Triangulation 12.1.2 Data Source 12.1.2.1 Secondary Sources 12.1.2.2 Primary Sources 12.2 Author Details 12.3 Disclaimer List of Tables/GraphsList of TablesTable 1. Global Targeted Protein Degraders Sales (US$ Million) Growth Rate by Type (2021, 2025 & 2032) Table 2. Global Targeted Protein Degraders Sales (US$ Million) Comparison by Application (2021, 2025 & 2032) Table 3. Global Market Targeted Protein Degraders Market Size (US$ Million) by Region:2021 VS 2025 VS 2032 Table 4. Global Targeted Protein Degraders Sales (Dose) by Region (2021-2026) Table 5. Global Targeted Protein Degraders Sales Market Share by Region (2021-2026) Table 6. Global Targeted Protein Degraders Revenue (US$ Million) Market Share by Region (2021-2026) Table 7. Global Targeted Protein Degraders Revenue Share by Region (2021-2026) Table 8. Global Targeted Protein Degraders Sales (Dose) Forecast by Region (2027-2032) Table 9. Global Targeted Protein Degraders Sales Market Share Forecast by Region (2027-2032) Table 10. Global Targeted Protein Degraders Revenue (US$ Million) Forecast by Region (2027-2032) Table 11. Global Targeted Protein Degraders Revenue Share Forecast by Region (2027-2032) Table 12. Global Targeted Protein Degraders Sales by Type (Dose) & (2021-2026) Table 13. Global Targeted Protein Degraders Sales Share by Type (2021-2026) Table 14. Global Targeted Protein Degraders Revenue by Type (US$ Million) & (2021-2026) Table 15. Global Targeted Protein Degraders Average Price by Type (US$/Dose) & (2021-2026) Table 16. Global Targeted Protein Degraders Sales by Type (Dose) & (2027-2032) Table 17. Global Targeted Protein Degraders Revenue by Type (US$ Million) & (2027-2032) Table 18. Global Targeted Protein Degraders Average Price by Type (US$/Dose) & (2027-2032) Table 19. Representative Players of Each Type Table 20. Global Targeted Protein Degraders Sales by Application (Dose) & (2021-2026) Table 21. Global Targeted Protein Degraders Sales Share by Application (2021-2026) Table 22. Global Targeted Protein Degraders Revenue by Application (US$ Million) & (2021-2026) Table 23. Global Targeted Protein Degraders Average Price by Application (US$/Dose) & (2021-2026) Table 24. Global Targeted Protein Degraders Sales by Application (Dose) & (2027-2032) Table 25. Global Targeted Protein Degraders Revenue Market Share by Application (US$ Million) & (2027-2032) Table 26. Global Targeted Protein Degraders Average Price by Application (US$/Dose) & (2027-2032) Table 27. New Sources of Growth in Targeted Protein Degraders Applications Table 28. Global Targeted Protein Degraders Sales by Company (Dose) & (2021-2026) Table 29. Global Targeted Protein Degraders Sales Share by Company (2021-2026) Table 30. Global Targeted Protein Degraders Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Targeted Protein Degraders Revenue Share by Company (2021-2026) Table 32. Global Targeted Protein Degraders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degraders as of 2025) Table 33. Global Market Targeted Protein Degraders Average Price by Company (US$/Dose) & (2021-2026) Table 34. Global Key Manufacturers of Targeted Protein Degraders, Manufacturing Sites & Headquarters Table 35. Global Key Manufacturers of Targeted Protein Degraders, Product Type & Application Table 36. Global Key Manufacturers of Targeted Protein Degraders, Date of Entry into This Industry Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans Table 38. North America Targeted Protein Degraders Sales by Company (2021-2026) & (Dose) Table 39. North America Targeted Protein Degraders Sales Market Share by Company (2021-2026) Table 40. North America Targeted Protein Degraders Revenue by Company (2021-2026) & (US$ Million) Table 41. North America Targeted Protein Degraders Revenue Market Share by Company (2021-2026) Table 42. North America Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 43. North America Targeted Protein Degraders Sales Market Share by Type (2021-2026) Table 44. North America Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 45. North America Targeted Protein Degraders Sales Market Share by Application (2021-2026) Table 46. Europe Targeted Protein Degraders Sales by Company (2021-2026) & (Dose) Table 47. Europe Targeted Protein Degraders Sales Market Share by Company (2021-2026) Table 48. Europe Targeted Protein Degraders Revenue by Company (2021-2026) & (US$ Million) Table 49. Europe Targeted Protein Degraders Revenue Market Share by Company (2021-2026) Table 50. Europe Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 51. Europe Targeted Protein Degraders Sales Market Share by Type (2021-2026) Table 52. Europe Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 53. Europe Targeted Protein Degraders Sales Market Share by Application (2021-2026) Table 54. China Targeted Protein Degraders Sales by Company (2021-2026) & (Dose) Table 55. China Targeted Protein Degraders Sales Market Share by Company (2021-2026) Table 56. China Targeted Protein Degraders Revenue by Company (2021-2026) & (US$ Million) Table 57. China Targeted Protein Degraders Revenue Market Share by Company (2021-2026) Table 58. China Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 59. China Targeted Protein Degraders Sales Market Share by Type (2021-2026) Table 60. China Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 61. China Targeted Protein Degraders Sales Market Share by Application (2021-2026) Table 62. Japan Targeted Protein Degraders Sales by Company (2021-2026) & (Dose) Table 63. Japan Targeted Protein Degraders Sales Market Share by Company (2021-2026) Table 64. Japan Targeted Protein Degraders Revenue by Company (2021-2026) & (US$ Million) Table 65. Japan Targeted Protein Degraders Revenue Market Share by Company (2021-2026) Table 66. Japan Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 67. Japan Targeted Protein Degraders Sales Market Share by Type (2021-2026) Table 68. Japan Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 69. Japan Targeted Protein Degraders Sales Market Share by Application (2021-2026) Table 70. Arvinas Company Information Table 71. Arvinas Description and Business Overview Table 72. Arvinas Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 73. Arvinas Targeted Protein Degraders Product Table 74. Arvinas Recent Development Table 75. C4 Therapeutics Company Information Table 76. C4 Therapeutics Description and Business Overview Table 77. C4 Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 78. C4 Therapeutics Targeted Protein Degraders Product Table 79. C4 Therapeutics Recent Development Table 80. Kymera Therapeutics Company Information Table 81. Kymera Therapeutics Description and Business Overview Table 82. Kymera Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 83. Kymera Therapeutics Targeted Protein Degraders Product Table 84. Kymera Therapeutics Recent Development Table 85. Nurix Company Information Table 86. Nurix Description and Business Overview Table 87. Nurix Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 88. Nurix Targeted Protein Degraders Product Table 89. Nurix Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Description and Business Overview Table 92. Pfizer Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 93. Pfizer Targeted Protein Degraders Product Table 94. Pfizer Recent Development Table 95. Novartis Company Information Table 96. Novartis Description and Business Overview Table 97. Novartis Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 98. Novartis Targeted Protein Degraders Product Table 99. Novartis Recent Development Table 100. MSD Company Information Table 101. MSD Description and Business Overview Table 102. MSD Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 103. MSD Targeted Protein Degraders Product Table 104. MSD Recent Development Table 105. Foghorn Therapeutics Company Information Table 106. Foghorn Therapeutics Description and Business Overview Table 107. Foghorn Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 108. Foghorn Therapeutics Targeted Protein Degraders Product Table 109. Foghorn Therapeutics Recent Development Table 110. Dialectic Therapeutics Company Information Table 111. Dialectic Therapeutics Description and Business Overview Table 112. Dialectic Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 113. Dialectic Therapeutics Targeted Protein Degraders Product Table 114. Dialectic Therapeutics Recent Development Table 115. Accutar Biotech Company Information Table 116. Accutar Biotech Description and Business Overview Table 117. Accutar Biotech Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 118. Accutar Biotech Targeted Protein Degraders Product Table 119. Accutar Biotech Recent Development Table 120. Cullgen Company Information Table 121. Cullgen Description and Business Overview Table 122. Cullgen Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 123. Cullgen Targeted Protein Degraders Product Table 124. Cullgen Recent Development Table 125. Bristol-Myers Squibb Company Information Table 126. Bristol-Myers Squibb Description and Business Overview Table 127. Bristol-Myers Squibb Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 128. Bristol-Myers Squibb Targeted Protein Degraders Product Table 129. Bristol-Myers Squibb Recent Development Table 130. Monte Rosa Therapeutics Company Information Table 131. Monte Rosa Therapeutics Description and Business Overview Table 132. Monte Rosa Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 133. Monte Rosa Therapeutics Targeted Protein Degraders Product Table 134. Monte Rosa Therapeutics Recent Development Table 135. Proxygen Company Information Table 136. Proxygen Description and Business Overview Table 137. Proxygen Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 138. Proxygen Targeted Protein Degraders Product Table 139. Proxygen Recent Development Table 140. Dunad Therapeutics Company Information Table 141. Dunad Therapeutics Description and Business Overview Table 142. Dunad Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 143. Dunad Therapeutics Targeted Protein Degraders Product Table 144. Dunad Therapeutics Recent Development Table 145. Astellas Company Information Table 146. Astellas Description and Business Overview Table 147. Astellas Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 148. Astellas Targeted Protein Degraders Product Table 149. Astellas Recent Development Table 150. Origami Therapeutics Company Information Table 151. Origami Therapeutics Description and Business Overview Table 152. Origami Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 153. Origami Therapeutics Targeted Protein Degraders Product Table 154. Origami Therapeutics Recent Development Table 155. NEOsphere Biotechnologies Company Information Table 156. NEOsphere Biotechnologies Description and Business Overview Table 157. NEOsphere Biotechnologies Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 158. NEOsphere Biotechnologies Targeted Protein Degraders Product Table 159. NEOsphere Biotechnologies Recent Development Table 160. Ubiquigent Company Information Table 161. Ubiquigent Description and Business Overview Table 162. Ubiquigent Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 163. Ubiquigent Targeted Protein Degraders Product Table 164. Ubiquigent Recent Development Table 165. Kangpu Biopharmaceuticals Company Information Table 166. Kangpu Biopharmaceuticals Description and Business Overview Table 167. Kangpu Biopharmaceuticals Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 168. Kangpu Biopharmaceuticals Targeted Protein Degraders Product Table 169. Kangpu Biopharmaceuticals Recent Development Table 170. Ranok Therapeutics Company Information Table 171. Ranok Therapeutics Description and Business Overview Table 172. Ranok Therapeutics Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 173. Ranok Therapeutics Targeted Protein Degraders Product Table 174. Ranok Therapeutics Recent Development Table 175. BeiGene Company Information Table 176. BeiGene Description and Business Overview Table 177. BeiGene Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 178. BeiGene Targeted Protein Degraders Product Table 179. BeiGene Recent Development Table 180. Hinova Pharma Company Information Table 181. Hinova Pharma Description and Business Overview Table 182. Hinova Pharma Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 183. Hinova Pharma Targeted Protein Degraders Product Table 184. Hinova Pharma Recent Development Table 185. Haisco Pharmaceutical Company Information Table 186. Haisco Pharmaceutical Description and Business Overview Table 187. Haisco Pharmaceutical Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 188. Haisco Pharmaceutical Targeted Protein Degraders Product Table 189. Haisco Pharmaceutical Recent Development Table 190. CTTQ Company Information Table 191. CTTQ Description and Business Overview Table 192. CTTQ Targeted Protein Degraders Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 193. CTTQ Targeted Protein Degraders Product Table 194. CTTQ Recent Development Table 195. Production Base and Market Concentration Rate of Raw Material Table 196. Key Suppliers of Raw Materials Table 197. Targeted Protein Degraders Distributors List Table 198. Targeted Protein Degraders Customers List Table 199. Targeted Protein Degraders Market Trends Table 200. Targeted Protein Degraders Market Drivers Table 201. Targeted Protein Degraders Market Challenges Table 202. Targeted Protein Degraders Market Restraints Table 203. Research Programs/Design for This Report Table 204. Key Data Information from Secondary Sources Table 205. Key Data Information from Primary Sources List of Figures Figure 1. Targeted Protein Degraders Product Picture Figure 2. Global Targeted Protein Degraders Sales (US$ Million) by Type (2021, 2025 & 2032) Figure 3. Global Targeted Protein Degraders Sales Market Share by Type in 2025 & 2032 Figure 4. PROTAC Product Picture Figure 5. Molecular Glues Product Picture Figure 6. Other Ubiquitin-Proteasome System Technologies Product Picture Figure 7. Lysosomal System Technologies Product Picture Figure 8. Global Targeted Protein Degraders Sales (US$ Million) by Application (2021, 2025 & 2032) Figure 9. Global Targeted Protein Degraders Sales Market Share by Application in 2025 & 2032 Figure 10. Prostate Cancer Examples Figure 11. Breast Cancer Examples Figure 12. Lymphoma Examples Figure 13. Others Examples Figure 14. Global Targeted Protein Degraders Sales, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Targeted Protein Degraders Sales Growth Rate (2021-2032) & (US$ Million) Figure 16. Global Targeted Protein Degraders Sales (Dose) Growth Rate (2021-2032) Figure 17. Global Targeted Protein Degraders Price Trends Growth Rate (2021-2032) & (US$/Dose) Figure 18. Targeted Protein Degraders Report Years Considered Figure 19. Global Market Targeted Protein Degraders Market Size (US$ Million) by Region:2021 VS 2025 VS 2032 Figure 20. Global Targeted Protein Degraders Revenue Market Share by Region: 2021 VS 2025 Figure 21. North America Targeted Protein Degraders Revenue (US$ Million) Growth Rate (2021-2032) Figure 22. North America Targeted Protein Degraders Sales (Dose) Growth Rate (2021-2032) Figure 23. Europe Targeted Protein Degraders Revenue (US$ Million) Growth Rate (2021-2032) Figure 24. Europe Targeted Protein Degraders Sales (Dose) Growth Rate (2021-2032) Figure 25. China Targeted Protein Degraders Revenue (US$ Million) Growth Rate (2021-2032) Figure 26. China Targeted Protein Degraders Sales (Dose) Growth Rate (2021-2032) Figure 27. Japan Targeted Protein Degraders Revenue (US$ Million) Growth Rate (2021-2032) Figure 28. Japan Targeted Protein Degraders Sales (Dose) Growth Rate (2021-2032) Figure 29. Global Targeted Protein Degraders Revenue Share by Type (2021-2026) Figure 30. Global Targeted Protein Degraders Sales Share by Type (2027-2032) Figure 31. Global Targeted Protein Degraders Revenue Share by Type (2027-2032) Figure 32. Global Targeted Protein Degraders Revenue Share by Application (2021-2026) Figure 33. Global Targeted Protein Degraders Revenue Market Share by Application in 2021 & 2025 Figure 34. Global Targeted Protein Degraders Sales Share by Application (2027-2032) Figure 35. Global Targeted Protein Degraders Revenue Share by Application (2027-2032) Figure 36. Global Targeted Protein Degraders Sales Share by Company (2025) Figure 37. Global Targeted Protein Degraders Revenue Share by Company (2025) Figure 38. Global 5 Largest Targeted Protein Degraders Players Market Share by Revenue in Targeted Protein Degraders: 2021 & 2025 Figure 39. Targeted Protein Degraders Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. Manufacturing Cost Structure of Targeted Protein Degraders Figure 41. Manufacturing Process Analysis of Targeted Protein Degraders Figure 42. Targeted Protein Degraders Industrial Chain Figure 43. Channels of Distribution (Direct Vs Distribution) Figure 44. Distributors Profiles Figure 45. Bottom-up and Top-down Approaches for This Report Figure 46. Data Triangulation Figure 47. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（protein）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
